In a groundbreaking development in adult ADHD treatment, a new study published in Psychological Medicine reveals the clinical promise of a digital cognitive behavioral therapy (CBT) platform named attexis. This innovative digital intervention, born out of a collaboration among several renowned German institutions—including GAIA in Hamburg and multiple university medical centers—addresses a significant gap in ADHD care for adults, a population often underserved by traditional treatment modalities. The trial, a rigorously designed randomized controlled study involving 337 adult participants, unequivocally demonstrated that supplementing standard treatment as usual (TAU) with attexis for three months yields a statistically and clinically meaningful reduction in ADHD symptom severity.
The study’s implications resonate far beyond symptom relief. Attexis users showed marked improvements not only in core ADHD manifestations but also enjoyed gains in broader domains such as occupational and social functioning, self-esteem, and overall quality of life. Additionally, the digital intervention contributed to a notable diminution in comorbid depressive symptoms, underscoring its multidimensional therapeutic impact. These findings are particularly compelling when considering that the therapeutic effects of attexis rival those observed in conventional face-to-face psychotherapies, a realm historically considered the gold standard but often hampered by accessibility issues and resource constraints.
At the heart of attexis’ efficacy lies its evidence-based design, integrating CBT principles with mindfulness techniques into a user-friendly, conversational framework. This self-guided digital platform offers psychoeducation and tailored therapeutic strategies through interactive dialogues, augmented by self-monitoring tools and timely reminders to reinforce adherence and engagement. Such design allows for seamless integration of the digital therapy into existing healthcare regimens without overburdening clinical resources or requiring continuous therapist involvement.
The advent of attexis arrives at a critical juncture for adult ADHD care, particularly in Germany and Europe, where diagnostic rates have surged—tripling since 2015—yet treatment accessibility remains woefully inadequate. Despite an estimated two million adults living with ADHD in Germany alone, many face prolonged waits for specialized psychotherapy or receive pharmacological interventions without concurrent psychosocial support. The shortage of trained therapists adept in adult ADHD-focused CBT exacerbates this gap, making scalable digital solutions like attexis indispensable in bridging these care deficits.
Key to the advancement of this intervention’s clinical adoption was its permanent inclusion in Germany’s DiGA directory by the Federal Institute for Drugs and Medical Devices (BfArM) in August 2025. This regulatory milestone endorses attexis as a reimbursable digital health application, enabling physicians and psychotherapists to prescribe the therapy with full coverage by statutory health insurance. Such integration not only affirms clinical confidence in digital therapeutics but also paves the way for widespread patient access, thereby transforming the landscape of ADHD management.
Dr. Gitta Jacob, head of research and development at GAIA, emphasized the significance of the findings: “Our randomized controlled trial provides robust evidence supporting digital CBT-based interventions as effective, user-friendly options for adults with ADHD. We are proud to contribute meaningfully to closing the therapeutic gap with accessible and scalable solutions.” Her remarks highlight the convergence of technological innovation and clinical rigor that defines attexis’ development.
The multidimensional therapeutic approach of attexis is grounded in its dual focus on cognitive restructuring and mindfulness practices, designed to enhance self-regulation and adaptive coping strategies. By delivering psychoeducational content and therapeutic exercises through an engaging, conversational interface, the intervention ensures sustained user interaction and personalization. Self-monitoring features empower patients to track symptom fluctuations and behavioral patterns, fostering greater self-awareness and facilitating data-driven adjustments to their treatment.
Importantly, the clinical trial rigorously compared the intervention group receiving attexis plus TAU with a control group receiving TAU alone. The statistically significant improvements highlight attexis’ additive benefit rather than an isolated effect, reinforcing its role as a complement rather than replacement for existing therapies. Metrics of social and occupational functioning alongside psychological parameters such as self-esteem and depressive symptomatology were robustly improved, reflecting the intervention’s holistic impact on patients’ lives.
Beyond the direct therapeutic benefits, attexis represents an emblematic advance in digital health technology’s application to chronic mental health conditions. Leveraging automation and self-guided methodologies, it circumvents traditional barriers like geographic location, therapist availability, and scheduling conflicts. For adults balancing complex life demands, such an accessible intervention augments treatment flexibility and adherence.
GAIA’s two-decade leadership in digital therapeutics underpins the scientific credibility of attexis. Their extensive portfolio, backed by over 30 randomized controlled trials and meta-analyses, underscores an unwavering commitment to evidence-based digital health. This expertise spans a broad therapeutic spectrum, including mental health and other chronic conditions, underscoring attexis as part of a continuum of validated digital interventions aimed at improving patient outcomes on a global scale.
Overall, the emergence of attexis signals a transformative era in ADHD care, where digital therapeutics enhance treatment scalability without compromising clinical efficacy. By harnessing cognitive behavioral principles through an accessible platform, it affords adults with ADHD renewed hope for symptom management, improved functioning, and enhanced quality of life. As healthcare systems globally grapple with growing demand for mental health services, attexis exemplifies a forward-thinking strategy to effectively democratize specialized interventions for this often neglected population.
Subject of Research: People
Article Title: Effectiveness of attexis, a digital intervention based on cognitive behavioral therapy for adults with ADHD: a randomized controlled trial
News Publication Date: 11-Mar-2026
References:
Ivanova M, Holstiege J, Akmatov MK, Müller D, Kohring C. The Incidence of AD(H)D-Spectrum Disorders in Adults. Dtsch Ärztebl. 2025;122. doi:10.3238/arztebl.m2025.0167
Image Credits: D’Amelio, R., et al., (2026) Effectiveness of attexis, a digital intervention based on cognitive behavioral therapy for adults with ADHD: a randomized controlled trial. Psychological Medicine
Keywords: ADHD, digital therapy, cognitive behavioral therapy (CBT), attexis, adult ADHD, DiGA, digital health application, randomized controlled trial, mental health, digital therapeutics, mindfulness, adult psychiatry
